Vivek M. Rangnekar
Affiliations: | University of Kentucky, Lexington, KY |
Area:
Microbiology Biology, Molecular Biology, Cell BiologyGoogle:
"Vivek Rangnekar"Children
Sign in to add trainee| Nadia M. El-Guendy | grad student | 2002 | University of Kentucky |
| Krishna M. Vasudevan | grad student | 2005 | University of Kentucky |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Subburayan K, Thayyullathil F, Pallichankandy S, et al. (2024) Tumor suppressor Par-4 activates autophagy-dependent ferroptosis. Communications Biology. 7: 732 |
| Burikhanov R, Ganguly S, Ellingson S, et al. (2023) Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. American Journal of Cancer Research. 13: 976-991 |
| Ding N, Jiang H, Thapa P, et al. (2022) Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt/GSK3 signaling pathways. The Journal of Biological Chemistry. 102123 |
| Mello-Andrade F, Guedes APM, Pires WC, et al. (2021) Ru(II)/amino acid complexes inhibit the progression of breast cancer cells through multiple mechanism-induced apoptosis. Journal of Inorganic Biochemistry. 226: 111625 |
| Thayyullathil F, Cheratta AR, Pallichankandy S, et al. (2020) Par-4 regulates autophagic cell death in human cancer cells via upregulating p53 and BNIP3. Biochimica Et Biophysica Acta. Molecular Cell Research. 118692 |
| Kim K, Araujo P, Hebbar N, et al. (2019) Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer. Protein Engineering, Design & Selection : Peds |
| Greene JT, Mani R, Ramaswamy R, et al. (2019) Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling. Blood Advances. 3: 1255-1266 |
| Wang P, Burikhanov R, Jayswal R, et al. (2018) Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors. Genes & Cancer. 9: 190-197 |
| He C, Plattner R, Rangnekar V, et al. (2018) Potential protein markers for breast cancer recurrence: a retrospective cohort study. Cancer Causes & Control : Ccc |
| Araujo N, Hebbar N, Rangnekar VM. (2018) GRP78 Is a Targetable Receptor on Cancer and Stromal Cells. Ebiomedicine |